GlassScriptPhysician profile
Dustin E Stevenson
NPI 1962610279
$1,813.26
in general payments reported to CMS, 2019-2025
25 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.33 · 2021: $135 · 2022: $395 · 2023: $709 · 2024: $128 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.87 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $245.02 | 2021-2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $236.98 | 2020-2025 | |
| Amgen INC. | $167.37 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.35 | 2023 | |
| Daiichi Sankyo INC. | $124.23 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $117.47 | 2022-2025 | Imfinzi, Enhertu |
| Celgene Corporation | $101.98 | 2023-2025 | Reblozyl, Pomalyst |
| Seagen INC. | $82.69 | 2022 | |
| Gilead Sciences, INC. | $60.04 | 2021-2023 | Trodelvy |
| Abbvie INC. | $56.31 | 2024-2025 | |
| Pfizer INC. | $49.12 | 2023-2025 | |
| Genentech USA, INC. | $44.99 | 2022-2023 | Tecentriq |
| Janssen Biotech, INC. | $43.87 | 2022-2023 | Erleada |
| Exelixis INC. | $43.41 | 2022-2025 | Cabometyx |
| Beigene USA, INC. | $42.44 | 2023 | Brukinsa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $34.35 | 2025 | Besremi |
| Puma Biotechnology, INC. | $29.98 | 2023 | |
| Taiho Oncology, INC. | $27.84 | 2023 | |
| Sobi, INC | $27.25 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $26.14 | 2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $25.84 | 2023 | Alunbrig |
| Progenics Pharmaceuticals, INC. | $25.23 | 2023 | Pylarify |
| Verity Pharmaceuticals INC. | $24.83 | 2023 | Trelstar |
| Merck Sharp & Dohme LLC | $19.30 | 2025 | Keytruda Qlex, Keytruda |
| Kite Pharma, INC. | $18.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.